Skip to main content

We are committed to fostering strong partnerships to develop and advance gene-edited therapies. If you are interested in partnering with Caribou, please contact our team.

Our Partners


In February 2021, Caribou and AbbVie entered into a collaboration and license agreement for the research and development of CAR-T cell products. Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie. AbbVie will have exclusive rights to Caribou’s next-generation Cas12a chRDNA genome editing and cell therapy technologies for the selected targets. Caribou will conduct certain pre-clinical research, development, and manufacturing activities for the collaboration programs, and AbbVie will reimburse Caribou for all such activities pursuant to the collaboration. AbbVie is responsible for all clinical development, commercialization, and manufacturing efforts. AbbVie has the option to pay a fee to expand the collaboration to include up to an additional two CAR-T cell therapies. View Press Release.

The Leukemia & Lymphoma Society

In March 2021, Caribou announced a $115M Series C financing. As a part of the capital raise, Caribou received a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) directed toward advancing CB-010, the company’s allogeneic CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma. LLS is a global leader in the fight against cancer with a mission to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS TAP is a strategic initiative that builds business alliances and collaborations with biotechnology companies and academic researchers to identify potential breakthrough therapies with the ability to improve the standard of care. LLS TAP funds late-stage pre-clinical studies and proof of concept or registrational clinical trials to help advance therapeutics along the drug development and approval pathway. To learn more, visit